Susan Cohen, Megan Gates and Joel Papernik, Members in the Immigration and Corporate practices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., will moderate panels at the BIO HR Conference and the BIO International Convention being held at the Georgia World Congress Center in Atlanta beginning Monday, May 18.
Susan Cohen, an internationally recognized expert in Immigration law and founder of the Firm's Immigration section, will chair a panel entitled "Cutting Edge Immigration Solutions and Best Practices: How to Land and Retain Foreign Talent and Keep Your Company Out of Trouble in the Bargain." Her panel will take place on Monday, May 18 from 2:45 - 4 pm. Among other things, this session will provides HR managers and specialists, General Counsel, CFO's, COO's and others who are responsible for immigration matters with creative solutions to immigration obstacles, including how to quickly bring a new hire on board when the H-1B visa quota has been reached; how to make the most effective use of the business visitor visa; and, how to avoid security-related visa processing delays. Mintz Levin is also a sponsor of the HR Strategic and HR Global tracks at the BIO Human Resources Conference.
Ms. Gates, who is a Member in the Firm's Corporate practice and Co-Chair of the Firm's Securities Practice Group will participate in a panel entitled, "What to Say, When and How: Navigating the Regulatory Minefield." The panel discussion, which is on Tuesday, May 19 from 10-11:30am, will look at how the failure to effectively communicate clinical trial results and FDA actions can result in stock price declines, angry stockholders, EMEA, FDA and SEC investigations, delays in future trials and compromised patient safety. The panel will address the legal, regulatory, market and public affairs concerns that arise when managing disclosures appropriately. The panelists will discuss their experiences and share suggestions for best practices and navigating the minefield of disclosure in the life sciences world.
Mr. Papernik, also a Member in the firm's Corporate practice, will chair a panel entitled "Biotech M&A - How to Sell Your Company in an Environment of Consolidation" on Tuesday, May 19 from 10-11:30am. It will examine consolidation among biotechs as an increasingly important and expanding trend in the life-sciences arena and it will present information on how emerging biotechs can prepare for the possibility of an acquisition. The panelists will discuss the various types of M&A biotech transactions and the risks involved, the ways in which target companies can successfully navigate through the acquisition process and alternative financing structures to facilitate making transactions. Mr. Papernik's panel has been chosen by The Burrill Report as one of a top selection of panels to see at BIO 2009.
Mintz Levin's attorneys have closed hundreds of transactions in the biotechnology sector in the past two years including 117 venture capital transactions totaling $1 billion, 128 mergers and acquisitions totaling $45 billion, 33 public offerings totaling $2.8 billion and 168 other financings (PIPEs, private placements, SPACs and fund formations) totaling over $ 7.9 billion.
Mintz Levin has an impressive track record working with and lobbying government entities involved in immigration and naturalization matters, including the U.S. Citizenship and Immigration Services (USCIS), the State Department (including government decision-makers abroad), and the Department of Labor. Our far-reaching network of contacts and other resources consistently benefit clients on both routine and extraordinary matters and we are particularly skilled at getting the attention of consular officials making critical decisions on visa applications and permanent residence applications for our clients.
Mintz Levin is an AmLaw 100 law firm with offices in the US and the UK. The firm has exceptional depth in a broad range of practice areas, but our clients recognize that what sets us apart from other law firms is our industry focus. By truly understanding business drivers and industry trends, we are able to provide our clients with more than just legal advice; we provide legal solutions to our clients' business issues. Since 1933, our lawyers have represented entrepreneurs, emerging growth companies, Fortune 500 companies, government agencies, not-for-profit organizations and leaders in primary industries that include Life Sciences/Biotechnology; Technology & Communications; Energy & Clean Technology; Financial Services & Insurance; Healthcare; Real Estate, Hospitality & Construction; and Retail & Consumer Products. Our practical knowledge combined with our industry expertise enables us to provide our clients with enterprise legal advice that gives their business a competitive advantage in the marketplace.